


C U R R I C U L U M V I T A E

DAMIANO MARASTONI

	Address  Telephone +393485947983 E-mail damiano.marastoni@univr.it  Sex Male Date of birth  Nationality Italian
CURRENT POSITION	<u>November 2019 to present:</u> Attending Neurologist at the outpatient clinic and at the Day Hospital Service, Regional Multiple Sclerosis Center (Prof. Massimiliano Calabrese), Neurology B, University of Verona PREVIOUS POSITIONS <u>January 2020 to December 2022:</u> Neurologist/medical care activity at Neurology A – Stroke Unit – AOUI Verona (Director Dr. Bruno Bonetti) <u>October 2019 to September 2022:</u> PhD Student in Neuroscience, Psychological and Psychiatric Sciences, and Movement Sciences at the Dept. of Neurological and Biomedical and Movement Sciences, University of Verona Neurology, University of Verona, Italy. PhD project: 'Immunopathology of intrathecal inflammation in MS: clinical and radiological correlates'. Supervisors: Prof. Massimiliano Calabrese, Dr.ssa Roberta Magliozzi <u>December 2021 to December 2022:</u> Research Grant (sponsored by Sanofi): 'Sviluppo ed ottimizzazione di un protocollo di acquisizione ed elaborazione delle immagini di risonanza magnetica nucleare ottenute dall'utilizzo di sequenze non convenzionali per identificare le lesioni croniche attive nei pazienti affetti da sclerosi multipla' <u>December 2019 to November 2021:</u> Research grant (sponsored by Biogen Idec) 'Improvement of radiological and immunological management of patients suffering at MS Center of Verona' <u>October 2018 to February 2019:</u> - Honorary Research Fellow at Multiple Sclerosis Tissue Bank (Prof. R. Reynolds), Wolfson Neurosciences Laboratories, Division of Brain Sciences, Imperial College London, Hammersmith Hospital Campus, London, UK - Honorary Observer at Outpatient Multiple Sclerosis Clinic (Prof. R. Nicholas) at Charing Cross Hospital, Imperial College Healthcare Trust, London, UK

INTERNATIONAL EXPERIENCES AND COLLABORATIONS	<u>November 2015 to November 2019:</u> Resident in Neurology, University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. Thesis: ‘Perivenular inflammation and active lesions at the time of death are associated with rapidly progressive multiple sclerosis (Supervisors Prof. M. Calabrese, Dr.ssa R. Magliozzi) <u>February 2015:</u> Italian Medical Council State Examination, full marks, Verona, Italy <u>July 2014:</u> Medical Degree, full marks with honours at University of Verona, Italy. Thesis title: ‘Glial Fibrillary Acidic Protein: a diagnostic marker in Neuromyelitis Optica?’ (Supervisor Prof. Bruno Bonetti) <u>June 2006:</u> High School Diploma, full marks, classical studies
	<u>October 2018 – February 2019:</u> Honorary research fellow at Multiple Sclerosis Tissue Bank (Prof. R. Reynolds), Wolfson Neurosciences Laboratories, Hammersmith Hospital Campus, Imperial College London, UK and Honorary observer at Outpatient Multiple Sclerosis Clinic (Prof. R. Nicholas) at Charing Cross Hospital, Imperial College London, UK. <i>Membership:</i> -European Academy of Neurology -Italian Neurology Society -Italian Neuroimmunology Society <i>External collaborations (ongoing projects):</i> Prof. Lawrence Steinman, Stanford University, USA. Prof. Richard Nicholas, Prof. Richard Reynolds, Imperial College London Dr. Antonio Scalfari, Imperial College London, UK Prof. Luca Battistini, Prof.ssa Giovanna Borsellino, Dr. Valerio Chiurchiù, IRCSS Santa Lucia, Rome, Italy Prof. Roberto Furlan, Università San Raffaele Prof. Nicola De Stefano, Dr. Marco Battaglini, University of Siena

AREAS OF RESEARCH	Multiple Sclerosis and other Central Nervous System demyelinating disorders Neuroimmunology – Neuropathology <i>I'm primarily involved in the subsequent projects and research fields (Supervisor Prof. M. Calabrese):</i> Lab activity: Coordination of neuroimmunological lab activities (from January 2022), including sample collection and analysis for clinical trials, proteomic analysis, RNA collection from CSF, processing of blood and CSF samples for subsequent flow cytometry analysis, snRNAseq planning and execution in collaboration with facilities at University of Verona. Tutorial Clinical and Research Activity Medical and Nursing Students: Former students: -Benedetti Giulia, MD. Thesis co-supervisor: 'Low dose' dimethyl fumarate for multiple sclerosis: safety, efficacy and effects on lymphocyte count'. Graduation July 2020. -Biondani Tommaso, MD. Thesis co-supervisor: 'Efficacia del trattamento con ocrelizumab nei pazienti affetti da Sclerosi Multipla: analisi combinata del profilo clinico, immunologico e di risonanza magnetica'. Graduation, July 2020. -Carraro Anna Giulia, NP. Thesis co-supervisor: 'La percezione della qualità di vita nel paziente con Sclerosi Multipla in trattamento con cladribina ("Mavenclad")': Studio descrittivo esplorativo attraverso l'utilizzo dei Patient Reported Outcomes'. Graduation, April 2021. Current students: - Aldrighetti Laura, medical student: thesis co-supervisor. Project ongoing: Intrathecal inflammatory profile, cortical damage, and prediction of disability progression independent of relapses in early multiple sclerosis (end: March 2023) - Eccher Chiara, medical student: thesis co-supervisor. Project ongoing: 'Exploring the intrathecal anti-inflammatory effect of cladribine in patients with RRMS (end: July 2023) - Alberti Maja, medical student: thesis co-supervisor. Project ongoing: A detailed immunological characterization of CSF profile in RRMS and SPMS patients (end: July 2023) - Tarter Francesca, medical student: thesis co-supervisor. Project ongoing: Predictive value of CSF markers on slowly expanding lesions in multiple sclerosis (end: October 2023) Neurology Residents: - Schiavi GianMarco, MD: project co-supervisor. Project: Long-term impact of cortical pathology on Multiple Sclerosis disability accumulation and cognitive impairment (end: November 2022) - Scartezzini Arianna, MD. Project co-supervisor: research activity on Osteopontin as a biomarker of cortical atrophy in MS and 'Mirror Study': incidence and significance of mirror pattern at the time of lumbar puncture for suspicion MS - Bolzan Anna, MD. Research activity on spinal cord atrophy in people with MS and its correlation with intrathecal inflammation.
CLINICAL TRIALS	Clinical Trials and Observational studies I Participate/participated in the subsequent clinical trials:

	- Study: MS700568_0022, A 2-year prospective study to evaluate the onset of action of Mavenclad® in subjects with highly active relapsing multiple sclerosis. Sponsor: Merck. - Study: 215MS202: AFFINITY Study - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies. Sponsor: Biogen Role: Evaluating physician - Study: MN39158 - A Single Arm, Open Label Multicentre Extension Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Multiple Sclerosis Previously Enrolled In A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trials. Sponsor: F.Hoffmann-La Roche Ltd Role: Treating physician -Study: OMB157G23101 - A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod. Sponsor: Novartis Role: Treating physician -Study: MS200527_0080 - A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 1). Sponsor: Merck Role: Evaluating physician -Study: MN39159 - CONSONANCE - An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis. Sponsor: F. Hoffmann La Roche Ltd Role: Treating physician -Study: CLOU064C12301 - A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib. Sponsor: Novartis Pharma AG Role: neurologist - MS700568_0151 - CLADFIT-MS. An observational, multicenter, prospective, phase IV study evaluating cladribine tablets' effects on PROs and their correlation with clinical and biometric parameters using Health Technology in subjects with highly-active RMS at their first switch. Sponsor: Merck Role: evaluating neurologist -Clinical trial, Phase IV, CLAD-19 - Exploring the intrathecal anti-inflammatory effect of cladribine and its relationship with clinical efficacy. EudraCT: 2018-004947-21. Sponsor: Azienda Ospedaliera Universitaria Integrata (A.O.U.I) – U.O.C. di Neurologia B. PI: Prof. Massimiliano Calabrese. Primary end-point: to verify whether decrease in the CSF levels of CXCL13 after 2 years of cladribine treatment is related to clinical response. Role: treating neurologist, analysis and interpretation of immunological data. - Clinical trial, Phase IV, SIPO20 - Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis. EudraCT: 2020-005947-22 Azienda Ospedaliera Universitaria Integrata di Verona – U.O.C. di Neurologia B - Azienda
--	--

	ospedaliero-universitaria Careggi, Dipartimento di Neuroscienze, Farmaco e Salute Bambino, Università di Firenze - Dipartimento di Scienze Mediche, Università di Torino - ASL "Città di Torino". PI: Prof. Massimiliano Calabrese. Role: treating neurologist, analysis and interpretation of immunological data (secondary end-points). - ESPRIMO Project (Esplorare, supportare e promuovere la resilienza in giovani adulti con sclerosi multipla). Coordinators Prof.ssa Michela Rimondini e Prof. Alberto Gajofatto, Dept. of Neurosciences, Biomedicine and Movement, University of Verona. Role: recruiting neurologist, EDSS assessment - OPPORTUNITY: Multicentric observational retrospective study: ‘Evaluating the effectiveness of Ocrelizumab in Primary Progressive Multiple sclerosis: a multicenter retrospective study’. Role: evaluating neurologist (PI Prof. M. Calabrese, Promoter Prof. F. Patti, University of Catania). - NoBE-L- No Better explanation nella diagnosi di Sclerosi Multipla: profilo liquorale delle principali patologie in diagnosi differenziale. Promoter: Azienda Ospedaliera Universitaria Integrata Verona – Neurologia B, PI: Prof. M. Calabrese. Role: coordination of CSF and immunological data collection and analysis.
--	--

PUBLICATIONS	International Journals with Impact factor (last five years) Mazziotti V, Crescenzo F, Tamanti A, Dapor C, Ziccardi S, Guandalini M, Colombi A, Camera V, Peloso A, Pezzini F, Turano E, Marastoni D, Calabrese M. Immune Response after COVID-19 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs. Biomedicines. 2022 Nov 24;10(12):3034. doi: 10.3390/biomedicines10123034. IF 4.757. Schiavetti I, Carmisciano L, Ponzano M, Cordioli C, Cocco E, Marfia GA, Inglese M, Filippi M, Radaelli M, Bergamaschi R, Immovilli P, Capobianco M, De Rossi N, Brichetto G, Scandellari C, Cavalla P, Pesci I, Confalonieri P, Perini P, Trojano M, Lanzillo R, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M, Sormani MP; MuSC-19 study group. Eur Signs and symptoms of Covid-19 in patients with multiple sclerosis. J Neurol. 2022 Sep 10. doi: 10.1111/ene.15554. IF 6.682. Marastoni D, Pisani AI, Schiavi G, Mazziotti V, Castellaro M, Tamanti A, Bosello F, Crescenzo F, Ricciardi GK, Montemezzi S, Pizzini FB, Calabrese M. CSF TNF and osteopontin levels correlate with the response to dimethyl fumarate in early multiple sclerosis. Ther Adv Neurol Disord. 2022 Jun 21;15:17562864221092124. doi: 10.1177/17562864221092124. IF 6.430. Marastoni D, Crescenzo F, Pisani AI, Zuco C, Schiavi G, Benedetti G, Ricciardi GK, Montemezzi S, Pizzini FB, Tamanti A, Calabrese M. Two years' effect of dimethyl
---------------------	--

fumarate on focal and diffuse gray matter pathology in multiple sclerosis. *Mult Scler.* 2022 Jun 28;13524585221104014. doi: 10.1177/13524585221104014. IF 5.855.

Guerrera G, Mandelli A, Finardi A, Orrico M, D'Orso S, Picozza M, Noviello M, Beretta V, Bonetti B, Calabrese M, Marastoni D, De Rossi N, Capra R, Salvetti M, Buscarinu MC, Inglese M, Uccelli A, Moiola L, Raposo C, Muros-Le Rouzic E, Pedotti R, Filippi M, Bonini C, Battistini L, Borsellino G, Furlan R. Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. *Mult Scler.* 2022 Jun 20;13524585221102158. doi: 10.1177/13524585221102158. IF 5.855.

Magliozzi R, Fadda G, Brown RA, Bar-Or A, Howell OW, Hametner S, Marastoni D, Poli A, Nicholas R, Calabrese M, Monaco S, Reynolds R. "Ependymal-in" gradient of thalamic damage in progressive multiple sclerosis. *Ann Neurol.* 2022 Jun 24. doi: 10.1002/ana.26448. IF 11.274.

Pitteri M, Dapor C, DeLuca J, Chiaravallotti ND, Marastoni D, Calabrese M. Slowing processing speed is associated with cognitive fatigue in newly diagnosed multiple sclerosis patients. *J Int Neuropsychol Soc.* 2022 Apr 25:1-7. doi: 10.1017/S1355617722000157. Online ahead of print. PMID: 35465860. IF 3.114.

Bergamaschi R, Ponzano M, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, Immovilli P, Capobianco M, De Rossi N, Bricchetto G, Cocco E, Scandellari C, Cavalla P, Pesci I, Zito A, Confalonieri P, Marfia GA, Perini P, Inglese M, Trojano M, Brescia Morra V, Pisoni E, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M, Sormani MP; MuSC-19 study group. The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. *Eur J Neurol.* 2022 Feb;29(2):535-542. doi: 10.1111/ene.15167. Epub 2021 Nov 15. PMID: 34735749. IF 6.288.

Sormani MP, Schiavetti I, Carnisciano L., et al. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. *Neurol Neuroimmunol Neuroinflamm.* 2021 Nov 9;9(1):e1105. doi: 10.1212/NXI.0000000000001105. IF 11.360.

Marastoni D, Magliozzi R, Bolzan A, Pisani AI, Rossi S, Crescenzo F, Montemezzi S, Pizzini FB, Calabrese M. CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm.* 2021 Sep 29;8(6):e1083. doi: 10.1212/NXI.0000000000001083. IF 11.360.

Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, Bensa C, De Rossi N, Pelletier J, Cordioli C, Vukusic S, Moiola L, Kerschen P, Radaelli M, Théaudin M, Immovilli P, Casez O, Capobianco M, Ciron J, Trojano M, Stankoff B, Créange A, Tedeschi G, Clavelou P, Comi G, Thouvenot E, Battaglia MA, Moreau T, Patti F, De Sèze J, Louapre C; Musc-19; Covisep study groups. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. *Ann Clin Transl Neurol.* 2021 Aug;8(8):1738-1744. doi: 10.1002/acn3.51408. IF 5.430.

Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, Salvetti M; MuSC-19 Study Group. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. *Mult Scler.* 2021 Jul 30;13524585211035318. doi: 10.1177/13524585211035318. IF 6.312.

Pitteri M, Magliozzi R, Nicholas R, Ziccardi S, Pisani AI, Pezzini F, Marastoni D, Calabrese M. Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients. *Mult Scler.* 2021 Jul 30;13524585211032510. doi: 10.1177/13524585211032510. IF 6.312.

Bajrami A, Magliozzi R, Pisani AI, Pizzini FB, Crescenzo F, Marastoni D, Calabrese M. Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS. *Mult Scler*. 2021 Aug 11;13524585211031786. doi: 10.1177/13524585211031786. IF 6.312.

Pitteri M, Galazzo IB, Brusini L, Cruciani F, Dapor C, Marastoni D, Menegaz G, Calabrese M. Microstructural MRI Correlates of Cognitive Impairment in Multiple Sclerosis: The Role of Deep Gray Matter. *Diagnostics (Basel)*. 2021 Jun 16;11(6):1103. doi: 10.3390/diagnostics11061103. IF 3.992.

Magliozzi R, Pezzini F, Pucci M, Rossi S, Facchiano F, Marastoni D, Montagnana M, Lippi G, Reynolds R, Calabrese M. Changes in Cerebrospinal Fluid Balance of TNF and TNF Receptors in Naïve Multiple Sclerosis Patients: Early Involvement in Compartmentalised Intrathecal Inflammation. *Cells*. 2021 Jul 6;10(7):1712. doi: 10.3390/cells10071712. IF 7.666.

Crescenzo F*, Marastoni D*, Pisani AI, Tamanti A, Dapor C, Colombi A, Brillo A, Magliozzi R, Pizzini FB, Castellaro M, Calabrese M. The Prognostic Value of White-Matter Selective Double Inversion Recovery MRI Sequence in Multiple Sclerosis: An Exploratory Study. *Diagnostics (Basel)*. 2021 Apr 12;11(4):686. doi: 10.3390/diagnostics11040686. IF 3.992.

Calabrese M, Marastoni D, Crescenzo F, Scalfari A. Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients. *Curr Opin Neurol*. 2021 Mar 1. doi: 10.1097/WCO.0000000000000921. IF 6.283.

Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratini P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Musc-19 Study Group. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. *Ann Neurol*. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9. IF 11.274.

Magliozzi R, Pitteri M, Ziccardi S, Pisani AI, Montibeller L, Marastoni D, Rossi S, Mazziotti V, Guandalini M, Dapor C, Schiavi G, Tamanti A, Nicholas R, Reynolds R, Calabrese M. CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis. *Ann Clin Transl Neurol*. 2021 Mar;8(3):534-547. doi: 10.1002/acn3.51298. Epub 2021 Jan 23. IF 5.430.

Magliozzi R, Mazziotti V, Montibeller L, Pisani AI, Marastoni D, Tamanti A, Rossi S, Crescenzo F, Calabrese M. Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients. *Front Cell Neurosci*. 2020 Oct 16;14:569827. doi: 10.3389/fncel.2020.569827. eCollection 2020. IF 5.505.

Magliozzi R*, Marastoni D*, Calabrese M. The BAFF / APRIL system as therapeutic target in multiple sclerosis. *Expert Opin Ther Targets*. 2020 Nov;24(11):1135-1145. doi: 10.1080/14728222.2020.1821647. Epub 2020 Sep 24. IF 6.902.

Crescenzo F*, Marastoni D*, Bovo C, Calabrese M. Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy. *Mult Scler Relat Disord*. 2020 Sep;44:102372. doi: 10.1016/j.msard.2020.102372. Epub 2020 Jul 4. IF 4.339.

Magliozzi R, Scalfari A, Pisani AI, Ziccardi S, Marastoni D, Pizzini FB, Bajrami A, Tamanti A, Guandalini M, Bonomi S, Rossi S, Mazziotti V, Castellaro M, Montemezzi

S, Rasia S, Capra R, Pitteri M, Romualdi C, Reynolds R, Calabrese M. The CSF Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity. *Ann Neurol*. 2020 Sep;88(3):562-573. doi: 10.1002/ana.25786. Epub 2020 Jul 9. IF 10.422.

Marastoni D, Africa L, Peretti A, Bocci S, Insana L, Ferrari S, Ginanneschi F, Zanette G, Fabrizi GM, Giannini F. Sustained response to subcutaneous immunoglobulins in chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA): report of two cases and review of the literature. *J Neurol*. 2020 Aug;267(8):2353-2361. doi: 10.1007/s00415-020-09843-y. Epub 2020 Apr 28. IF 4.849.

Magliozzi R, Hametner S, Facchiano F, Marastoni D, Rossi S, Castellaro M, Poli A, Lattanzi F, Visconti A, Nicholas R, Reynolds R, Monaco S, Lassmann H, Calabrese M. Iron homeostasis, complement and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. *Ann Clin Transl Neurol*, 2019 Nov;6(11):2150-2163. doi: 10.1002/acn3.50893. Epub 2019 Nov 1. IF 3.493.

Magliozzi R*, Marastoni D*, Rossi S, Castellaro M, Mazziotti V, Pitteri M, Gajofatto A, Monaco S, Benedetti MD, Calabrese M. Increase of CSF inflammatory profile in a case of highly active multiple sclerosis. *BMC Neurol* 2019 Sep 26;19(1):231. doi: 10.1186/s12883-019-1455-7. IF 2.356.

Marastoni D, Buriani A, Pisani AI, Crescenzo F, Zuco C, Fortinguerra S, Sorrenti V, Marenda B, Romualdi C, Magliozzi R, Monaco S, Calabrese M. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study. *Front Immunol*. 2019 Jul 19;10:1666. doi: 10.3389/fimmu.2019.01666. eCollection 2019. IF 4.716.

Crescenzo F, Marastoni D, Zuco C, Pitteri M, Magliozzi R, Monaco S, Calabrese M. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis. *Mult Scler Relat Disord*. 2018 Nov 12;27:305-311. doi: 10.1016/j.msard.2018.11.009. PubMed PMID: 30453199. IF 2.725.

Marangi A, Gajofatto A, Marastoni D, Gobbin F, Guiotto F, Tonin P, Benedetti MD. A case of multiple sclerosis and necrotizing autoimmune myopathy with anti-SRP antibodies. *Mult Scler Relat Disord*. 2018 Jan;19:118-120. doi: 10.1016/j.msard.2017.11.015. IF 2.725.

Total publications: 30

Publication in the last 5 years: 30

First or co-first author: 9

Citations (Scopus): 416

Numero medio di citazioni per pubblicazione: 13.9

‘Impact factor medio per pubblicazione’: 6.13 (mediana 5.9, DS 2.6)

H-Index (Scopus): 7

Book Chapter

Massimiliano Calabrese, Francesco Crescenzo, Damiano Marastoni, Marco Pitteri e Francesca Benedetta Pizzini, *Manifestazioni neurologiche associate ad infezione da SARS-CoV-2 in Neurologia Clinica*, C. Angelini e L. Battistin, III ed., Esculapio Editore.

	Submitted papers: accepted Pitteri M, Vannucci M, Dapor C, Guandalini M, Daffinà A, Marastoni D, Calabrese M. Prominent role of executive functioning on the Phonemic Fluency Test in people with multiple sclerosis. Accepted, Journal of the International Neuropsychological Society. Bosello F*, Marastoni D*, Francesca Benedetta Pizzini FB, Zaffalon C, Andrea Zuliani A, Turri G, Mariotto S, Bonacci E, Pedrotti E, Calabrese M. Atypical Myelin Oligodendrocyte Glycoprotein Antibody–Associated Optic Neuritis and acute demyelinating polyneuropathy after SARS-CoV-2 infection: case report and literature review. Accepted, J Neuroimmunology.
--	--

SCIENTIFIC CONFERENCES	Selected Oral Presentations (Presenting author) Intrathecal inflammatory markers and grey matter damage predict progression independent of relapses in multiple sclerosis: a preliminary study, Marastoni D, Colato E, Pisani AI, Mazziotti V, Tamanti A, Colombi A, Camera V, Crescenzo F, Ziccardi S, Guandalini M, Turano E, Bonetti B, Scalfari A, Calabrese M. Progression independent of relapse in MS – Mestre 6-7 October 2022 Cortical lesion load at the diagnosis predict conversion to secondary progressive multiple sclerosis. Marastoni D, Schiavi GM, Pisani AI, Ziccardi S, Tamanti A, Colombi A, Guandalini M, Peloso A, Scalfari A, De Stefano N, Calabrese M. 8th EAN Congress Europe 2022, 25-28 June 2022. Cerebrospinal fluid levels of CXCL12 and Osteopontin: potential early marker of primary progressive multiple sclerosis. Marastoni D, Magliozzi R, Bolzan A, Pisani AI, Rossi S, Montemezzi S, Pizzini FB, Calabrese M XXIX AINI Congress, September 16-19, 2021. Ruolo delle cellule B nella Sclerosi Multipla, D. Marastoni. Webinar: Nuove evidenze sul ruolo delle cellule B nella Sclerosi multipla - 29 June 2021 Cerebrospinal fluid levels of CXCL12 and Osteopontin: potential early marker of primary progressive multiple sclerosis. Marastoni D, Magliozzi R, Bolzan A, Pisani AI, Rossi S, Montemezzi S, Pizzini FB, Calabrese M. 7th EAN, 2nd Virtual Congress, June 19-22 2021. ‘New approaches in the treatment of Multiple Sclerosis’, D. Marastoni. Neuron-Glial Interactions in Health and Diseases”, ‘Four season seminar” at University of Verona-26.02.2021 Substantial ‘ependymal-in’ gradient of thalamic damage in progressive multiple sclerosis pathology. Magliozzi R, Fadda G, Bar-Or A, Howell OW, Marastoni D, Poli A, R. A. Brown RA, Nicholas R, Monaco S, Calabrese M, Reynolds R. 6th Congress of the European Academy of Neurology – 1st Virtual Congress 2020. High levels of perivascular inflammation and active white matter lesions at time of death are associated with rapidly progressive multiple sclerosis . Marastoni D, Magliozzi R, Howell O, Roncaroli F, Muraro P, Friede T, Calabrese M, Reynolds R, Nicholas R. XXXV Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2019 ‘High Levels Of Perivascular Inflammation And Active White Matter Lesions At Time Of Death Are Associated With Rapidly Progressive Multiple Sclerosis’. Marastoni D, Magliozzi R, Howell O, Roncaroli F, Muraro P, Friede T, Calabrese M, Reynolds R, Nicholas R XXVIII AINI Congress, 8 May 2019. Correlation between CSF B-cell inflammation, macrophage activity and cortical pathology in multiple sclerosis at time of diagnosis. Marastoni D, Magliozzi R, Rossi S, Castellaro M, Farina G, Romualdi C, Facchiano F, Howell O, Reynolds R, Monaco S, Calabrese M. XLVIII Congresso Società Italiana di Neurologia (SIN) – Napoli, Italy 14-17 October 2017 Late increase and heterogeneous behaviour of peripheral blood NK cells in relapsing-remitting multiple sclerosis patients treated with dimethylfumarate. Marastoni D, Magliozzi R, Crescenzo F, Zuco C, Rossi S, Castellaro M, Monaco S, Calabrese M. XLVIII Congresso Società Italiana di Neurologia–Napoli, Italy- 14-17 October 2017
--	--

OTHER ACTIVITIES	Awards and Funding PI 450000 Euro, Bando Ricerca Finalizzata 2021 (2020-2021) con destinatario istituzionale regione Veneto, principal investigator, project GR-2021-12373041 - Change-promoting - “Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis“ Organizing committee/Scientific secretariat in national or international meeting - ‘Progression independent of relapse in MS’ – Mestre 6-7 October 2022: scientific secretariat and session moderation - ‘The Silent Disease Activity in MS:molecular and imaging biomarkers’ – Riva Del Garda, September 16 and 17, 2021: scientific secretariat, young session organization and sessions moderation - "L’importanza della Multidisciplinarietà per una scelta terapeutica appropriata", 23 Novembre 2022, Webinar, scientific secretariat Advisory Board and scientific committee -Identificazione e gestione del paziente affetto da sclerosi multipla progressiva - Verona 28 ottobre e 26 novembre 2021– Faculty - La gestione delle terapie ad alta efficacia nel paziente con SM – Verona, 22 giugno e 16 novembre 2022 – Faculty - Gruppo di miglioramento ‘Improve’ - Bologna, 18 febbraio e 06 maggio 2022 – Faculty - AURand:l’appropriatezza di Aubagio®(Teriflunomide) – Scientific Board – 21/6/2021 -MAVENCLAD® International Advisory Board Meeting, March 26th 2020 Ad hoc reviewer for international Journals: Inflammation, Frontiers in Neurology, Frontiers in Neuroscience, Cells. Other activities -Composition of PDTA for multiple sclerosis treatment at MS regional center at University of Verona -Member of GISM, Gruppo interdisciplinare sclerosi multipla at AOUI Verona -Multidiscipinar Clinical Cases discussion: meetings organization and cases presentation -Certified EDSS rater (www.neurostatus.net) -Regular attendance at national and international courses and congresses (ECTRIMS, SIN, EAN, AINI) with a specific focus of neuroinflammatory disorders. Selected courses: - XXII Course ‘La gestione italiana del paziente con Sclerosi Multipla’ - Orbassano (Torino), Italy 3-5 June 2019 - XVII Course ‘EEG e tecniche correlate’ - Tirrenia (Pisa), Italy 12-17 March 2018 - XX Advanced Course ‘Magnetic Resonance Techniques in Multiple Sclerosis’ - Milan, Italy 30-31 March 2017
LANGUAGES Mother language	Italian

<i>Other languages</i>	English			
(Common European Framework Of Reference For Languages)	Listening	Reading	Writing	Listening
	C1	C1	C1	C1
Computer Operating systems	Windows, Macintosh			
Software	Microsoft Office package, Macintosh iWork package Statistics: GraphPad PRISM, STATA, SPSS Image analysis: Image ProPlus, QuPath.			
Lab Instruments experience	Immunohistochemistry and Immunofluorescence ELISA, Multiplex assay, ELLA Confocal microscopy, images acquisition and morphometric analysis scRNAseq Workflow			

Dichiaro che tutti i fatti e gli stati indicati nel curriculum sono da ritenersi dichiarati ai sensi e per gli effetti degli artt. 46 e/o 47 del DPR 445/2000, con consapevolezza delle sanzioni penali nel caso di dichiarazioni non veritiere e falsità negli atti, richiamate dall'art. 76 del DPR 445/2000

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003

Verona, 7/1/2023

Dr. Damiano Marastoni

